OmniAb, Inc. has expanded its partner base to over 100 entities and grown its active discovery programs to more than 400 by the end of 2025, reflecting solid adoption of its multi-species transgenic antibody platform. This biological and AI-powered technology uniquely positions OmniAb in the competitive therapeutic discovery sector. However, financial results remain challenged with a $69 million operating loss in 2025, driven by ongoing development investments. Additionally, evolving U.S. and global healthcare pricing reforms pose risks to the realization of milestone and royalty revenues tied to partners’ commercial success.